Gut Dysbiosis and Increased Intestinal Permeability Drive microRNAs, NLRP-3 Inflammasome and Liver Fibrosis in a Nutritional Model of Non-Alcoholic Steatohepatitis in Adult Male Sprague Dawley Rats

References

• Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–555. doi:10.1053/j.gastro.2014.11.039
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019;70(3):531–544. doi:10.1016/j.jhep.2018.10.033
   PubMed Web of Science ®Google Scholar
• Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133. doi:10.1002/hep.29466
   PubMed Web of Science ®Google Scholar
• Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69(4):896–904. doi:10.1016/j.jhep.2018.05.036
   PubMed Web of Science ®Google Scholar
• Duarte SMB, Stefano JT, Miele L, et al. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: a prospective pilot study. Nutr Metab Cardiovasc Dis. 2018;28(4):369–384. doi:10.1016/j.numecd.2017.10.014
   PubMed Web of Science ®Google Scholar
• Tsuchida T, Lee YA, Fujiwara N, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol. 2018;69(2):385–395. doi:10.1016/j.jhep.2018.03.011
   PubMed Web of Science ®Google Scholar
• Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci. 2019;76(8):1541–1558. doi:10.1007/s00018-019-03011-w
   PubMed Web of Science ®Google Scholar
• Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation. 2019;103(1):e1–e13. doi:10.1097/TP.0000000000002480
   PubMed Web of Science ®Google Scholar
• Chen D, Le TH, Shahidipour H, Read SA, Ahlenstiel G. The role of gut-derived microbial antigens on liver fibrosis initiation and progression. Cells. 2019;8:11. doi:10.3390/cells8111324
   Web of Science ®Google Scholar
• Hills RD, Pontefract BA, Mishcon HR, Black CA, Sutton SC, Theberge CR. Gut microbiome: profound implications for diet and disease. Nutrients. 2019;11:7. doi:10.3390/nu11071613
   Web of Science ®Google Scholar
• Houghton D, Stewart CJ, Day CP, Trenell M. Gut microbiota and lifestyle interventions in NAFLD. Int J Mol Sci. 2016;17(4):447. doi:10.3390/ijms17040447
   Web of Science ®Google Scholar
• Pierantonelli I, Rychlicki C, Agostinelli L, et al. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD. Sci Rep. 2017;7(1):12200. doi:10.1038/s41598-017-11744-6
   Web of Science ®Google Scholar
• Asgharpour A, Cazanave SC, Pacana T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol. 2016;65(3):579–588. doi:10.1016/j.jhep.2016.05.005
   PubMed Web of Science ®Google Scholar
• Van Herck MA, Vonghia L, Francque SM. Animal models of nonalcoholic fatty liver disease-a starter’s guide. Nutrients. 2017;9:10. doi:10.3390/nu9101072
   Web of Science ®Google Scholar
• Oseini AM, Cole BK, Issa D, Feaver RE, Sanyal AJ. Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. Hepatol Int. 2018;12(1):6–16. doi:10.1007/s12072-017-9838-6
   PubMed Web of Science ®Google Scholar
• Lau JK, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol. 2017;241(1):36–44. doi:10.1002/path.4829
   Web of Science ®Google Scholar
• Veteläinen R, van Vliet A, van Gulik TM. Essential pathogenic and metabolic differences in steatosis induced by choline or methione-choline deficient diets in a rat model. J Gastroenterol Hepatol. 2007;22(9):1526–1533. doi:10.1111/j.1440-1746.2006.04701.x
   PubMed Web of Science ®Google Scholar
• Machado MV, Michelotti GA, Xie G, et al. Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One. 2015;10(5):e0127991. doi:10.1371/journal.pone.0127991
   PubMed Web of Science ®Google Scholar
• Kishida N, Matsuda S, Itano O, et al. Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine. BMC Gastroenterol. 2016;16(1):61. doi:10.1186/s12876-016-0477-5
   Web of Science ®Google Scholar
• Sanches SC, Ramalho LN, Augusto MJ, da Silva DM, Ramalho FS. Nonalcoholic steatohepatitis: a search for factual animal models. Biomed Res Int. 2015;2015:574832. doi:10.1155/2015/574832
   PubMed Web of Science ®Google Scholar
• de Moura RF, Ribeiro C, de Oliveira JA, Stevanato E, de Mello MA. Metabolic syndrome signs in Wistar rats submitted to different high-fructose ingestion protocols. Br J Nutr. 2009;101(8):1178–1184. doi:10.1017/S0007114508066774
   Web of Science ®Google Scholar
• Gómez-Lechón MJ, Donato MT, Martínez-Romero A, Jiménez N, Castell JV, O’Connor JE. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact. 2007;165(2):106–116. doi:10.1016/j.cbi.2006.11.004
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254. doi:10.1016/0003-2697(76)90527-3
   PubMed Web of Science ®Google Scholar
• Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009;75(23):7537–7541. doi:10.1128/AEM.01541-09
   PubMed Web of Science ®Google Scholar
• Rognes T, Flouri T, Nichols B, Quince C, Mahé F. VSEARCH: a versatile open source tool for metagenomics. PeerJ. 2016;4:e2584. doi:10.7717/peerj.2584
   PubMed Web of Science ®Google Scholar
• Quast C, Pruesse E, Yilmaz P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013;41(Databaseissue):D590–596. doi:10.1093/nar/gks1219
   PubMed Web of Science ®Google Scholar
• Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7(5):335–336. doi:10.1038/nmeth.f.303
   PubMed Web of Science ®Google Scholar
• Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60. doi:10.1186/gb-2011-12-6-r60
   PubMed Web of Science ®Google Scholar
• Liang W, Menke AL, Driessen A, et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One. 2014;9(12):e115922. doi:10.1371/journal.pone.0115922
   Web of Science ®Google Scholar
• Recena Aydos L, Aparecida do Amaral L, Serafim de Souza R, et al. Nonalcoholic fatty liver disease induced by high-fat diet in C57bl/6 models. Nutrients. 2019;11:12. doi:10.3390/nu11123067
   Web of Science ®Google Scholar
• de Lima VM, Oliveira CP, Alves VA, et al. A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. J Hepatol. 2008;49(6):1055–1061. doi:10.1016/j.jhep.2008.07.024
   Web of Science ®Google Scholar
• Ikawa-Yoshida A, Matsuo S, Kato A, et al. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet. Int J Exp Pathol. 2017;98(4):221–233. doi:10.1111/iep.12240
   Web of Science ®Google Scholar
• Matsumoto M, Hada N, Sakamaki Y, et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol. 2013;94(2):93–103. doi:10.1111/iep.12008
   PubMed Web of Science ®Google Scholar
• Sun WW, ShangGuan T, Zhu P, et al. Role of hepatic neuropeptide Y-Y1 receptors in a methionine-choline-deficient model of non-alcoholic steatohepatitis. Life Sci. 2020;245:117356. doi:10.1016/j.lfs.2020.117356
   Web of Science ®Google Scholar
• Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146(6):1513–1524. doi:10.1053/j.gastro.2014.01.020
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Soejima Y, Fukusato T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2012;18(19):2300–2308. doi:10.3748/wjg.v18.i19.2300
   PubMed Web of Science ®Google Scholar
• Honda T, Ishigami M, Luo F, et al. Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice. Metabolism. 2017;69:177–187. doi:10.1016/j.metabol.2016.12.013
   PubMed Web of Science ®Google Scholar
• Cortez-Pinto H, Borralho P, Machado J, et al. Microbiota modulation with synbiotic decreases liver fibrosis in a high fat choline deficient diet mice model of Non-Alcoholic Steatohepatitis (NASH). GE Port J Gastroenterol. 2016;23(3):132–141. doi:10.1016/j.jpge.2016.01.004
   Google Scholar
• Raubenheimer PJ, Nyirenda MJ, Walker BR. A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes. 2006;55(7):2015–2020. doi:10.2337/db06-0097
   PubMed Web of Science ®Google Scholar
• Wu G, Zhang L, Li T, Lopaschuk G, Vance DE, Jacobs RL. Choline deficiency attenuates body weight gain and improves glucose tolerance in ob/ob mice. J Obes. 2012;2012:319172. doi:10.1155/2012/319172
   Google Scholar
• Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):842–845. doi:10.1016/S0016-5085(98)70599-2
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi:10.1016/j.metabol.2015.12.012
   PubMed Web of Science ®Google Scholar
• Yang J, Liu Q, Cao S, et al. MicroRNA-145 increases the apoptosis of activated hepatic stellate cells induced by TRAIL through NF-κB signaling pathway. Front Pharmacol. 2017;8:980. doi:10.3389/fphar.2017.00980
   Web of Science ®Google Scholar
• Pirola CJ, Fernández Gianotti T, Castaño GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5):800–812. doi:10.1136/gutjnl-2014-306996
   PubMed Web of Science ®Google Scholar
• Gómez-Zorita S, Aguirre L, Milton-Laskibar I, et al. Relationship between changes in microbiota and liver steatosis induced by high-fat feeding-a review of rodent models. Nutrients. 2019;11:9. doi:10.3390/nu11092156
   Web of Science ®Google Scholar
• Demir M, Lang S, Martin A, et al. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: ready for prime time? J Gastroenterol Hepatol. 2020. doi:10.1111/jgh.15071
   Web of Science ®Google Scholar
• Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412–425.
   PubMed Web of Science ®Google Scholar
• Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764–775. doi:10.1002/hep.28356
   PubMed Web of Science ®Google Scholar
• Acharya C, Bajaj JS, Microbiota G. Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46(1):155–169. doi:10.1016/j.gtc.2016.09.013
   PubMed Web of Science ®Google Scholar
• Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601–609. doi:10.1002/hep.26093
   PubMed Web of Science ®Google Scholar
• Ishioka M, Miura K, Minami S, Shimura Y, Ohnishi H. Altered gut microbiota composition and immune response in experimental steatohepatitis mouse models. Dig Dis Sci. 2017;62(2):396–406. doi:10.1007/s10620-016-4393-x
   Web of Science ®Google Scholar
• Liu JP, Zou WL, Chen SJ, et al. Effects of different diets on intestinal microbiota and nonalcoholic fatty liver disease development. World J Gastroenterol. 2016;22(32):7353–7364. doi:10.3748/wjg.v22.i32.7353
   PubMed Web of Science ®Google Scholar
• Ferreira DM, Afonso MB, Rodrigues PM, et al. c-Jun N-terminal kinase 1/c-Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver. Mol Cell Biol. 2014;34(6):1100–1120. doi:10.1128/MCB.00420-13
   PubMed Web of Science ®Google Scholar
• Aranha MM, Cortez-Pinto H, Costa A, et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2008;20(6):519–525. doi:10.1097/MEG.0b013e3282f4710a
   PubMed Web of Science ®Google Scholar
• Jensen T, Abdelmalek MF, Sullivan S, et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68(5):1063–1075. doi:10.1016/j.jhep.2018.01.019
   PubMed Web of Science ®Google Scholar
• Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability–a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14:189.
   PubMed Web of Science ®Google Scholar
• Mouries J, Brescia P, Silvestri A, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71(6):1216–1228. doi:10.1016/j.jhep.2019.08.005
   PubMed Web of Science ®Google Scholar
• Jegatheesan P, Beutheu S, Freese K, et al. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats. Br J Nutr. 2016;116(2):191–203. doi:10.1017/S0007114516001793
   PubMed Web of Science ®Google Scholar
• Raso GM, Simeoli R, Iacono A, et al. Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet. J Nutr Biochem. 2014;25(1):81–90. doi:10.1016/j.jnutbio.2013.09.006
   PubMed Web of Science ®Google Scholar
• Abenavoli L, Falalyeyeva T, Boccuto L, Tsyryuk O, Obeticholic Acid: KN, New A. Era in the treatment of nonalcoholic fatty liver disease. Pharmaceuticals (Basel). 2018;11:4. doi:10.3390/ph11040104
   Google Scholar
• Cengiz M, Ozenirler S, Elbeg S. Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis. J Gastroenterol Hepatol. 2015;30(7):1190–1196. doi:10.1111/jgh.12924
   PubMed Web of Science ®Google Scholar
• Sui YH, Luo WJ, Xu QY, Hua J. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation. World J Gastroenterol. 2016;22(8):2533–2544. doi:10.3748/wjg.v22.i8.2533
   Web of Science ®Google Scholar
• Wree A, McGeough MD, Peña CA, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med (Berl). 2014;92(10):1069–1082. doi:10.1007/s00109-014-1170-1
   PubMed Web of Science ®Google Scholar
• Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011;12(5):408–415. doi:10.1038/ni.2022
   PubMed Web of Science ®Google Scholar
• Jain MR, Giri SR, Bhoi B, et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 2018;38(6):1084–1094. doi:10.1111/liv.13634
   PubMed Web of Science ®Google Scholar
• Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150(5):1147–1159.e1145. doi:10.1053/j.gastro.2016.01.038
   PubMed Web of Science ®Google Scholar
• Henkel J, Coleman CD, Schraplau A, et al. Induction of steatohepatitis (NASH) with insulin resistance in wildtype B6 mice by a western-type diet containing soybean oil and cholesterol. Mol Med. 2017;23:70–82. doi:10.2119/molmed.2016.00203
   Web of Science ®Google Scholar